Drug
Forodesine
Forodesine: highest development phase Phase 2, developed by BioCryst Pharmaceuticals. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Forodesine 200 mg NCT00501735 | Phase 2 | Cutaneous T-cell Lymphoma (CTCL), |
| forodesine hydrochloride (BCX-1777) NCT00095381 | Phase 2 | Leukemia, T-Cell |
| forodesine hydrochloride (BCX-1777) NCT00289549 | Phase 2 | Leukemia, Lymphocytic, Chronic |
| forodesine hydrochloride NCT00061880 | Phase 1/2 | Lymphoma |
| forodesine hydrochloride (BCX-1777) NCT00289562 | Phase 1/2 | B-cell Acute Lymphoblastic Leukemia |
| forodesine hydrochloride NCT00073944 | Phase 1 | Cancer |
| forodesine hydrochloride NCT00098332 | Phase 1 | Lymphoma |
Latest
No recent events.
Follow Forodesine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.